| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C225-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C225-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-08 |
| filingDate |
2009-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2edaaed4df10f67233e1affd8d8cc7ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a636f148d22e96aab7a0210df60c2fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3c345b4ab998335dc094f7ad75b7e5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2117788afa0d717ba0ed97b515d75e40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9bfe32a0a06b39078ee56058faf1081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92aeb8cc8b4584ce1dac9f4856c63591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c039a026e84568ab0a5f4ea3cb234c0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4c1a911f8c42468f0400a8a95f0ef2b |
| publicationDate |
2009-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009124809-A1 |
| titleOfInvention |
Process for preparing acyclic hcv protease inhibitors |
| abstract |
Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: n n n n n n n n n n The disclosed processes use S N Ar-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: n n n n n n n n n n and halogenated or sulfonated bromoquinoline compounds. |
| priorityDate |
2004-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |